ArticleAmerican journal of physiology. Heart and circulatory physiology2004
Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.
Article in American journal of physiology. Heart and circulatory physiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 64 citations in OpenAlex.
- Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?Cells · 2022Review
- Effects of Oleamide on the Vasomotor Responses in the Rat.Cannabis and cannabinoid research · 2020Article
- CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune Dysregulation.Frontiers in pharmacology · 2016Review
- Effects of the novel cannabinoid CB1 receptor antagonist PF 514273 on the acquisition and expression of ethanol conditioned place preference.Alcohol (Fayetteville, N.Y.) · 2014Article
- TRPV1 and SP: key elements for sepsis outcome?British journal of pharmacology · 2013Review
- TRPV1 ablation aggravates inflammatory responses and organ damage during endotoxic shock.Clinical and vaccine immunology : CVI · 2013Article
- Is the cardiovascular system a therapeutic target for cannabidiol?British journal of clinical pharmacology · 2013Review
- The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogen-related receptor α protein.British journal of pharmacology · 2011Article
- Endotoxin impairs cardiac hemodynamics by affecting loading conditions but not by reducing cardiac inotropism.American journal of physiology. Heart and circulatory physiology · 2010Article
- The effects of targeted deletion of cannabinoid receptors CB1 and CB2 on intranasal sensitization and challenge with adjuvant-free ovalbumin.Toxicologic pathology · 2010Article
- Endocannabinoids and cardiac contractile function: pathophysiological implications.Pharmacological research · 2009Review
- The future of endocannabinoid-oriented clinical research after CB1 antagonists.Psychopharmacology · 2009Article
- Endocannabinoids and the heart.Journal of cardiovascular pharmacology · 2009Review
- Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.Journal of leukocyte biology · 2008Article
- Increased fear- and stress-related anxiety-like behavior in mice lacking tuberoinfundibular peptide of 39 residues.Genes, brain, and behavior · 2008Article
- Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).Naunyn-Schmiedeberg's archives of pharmacology · 2008Review
- TRPV1-mediated protection against endotoxin-induced hypotension and mortality in rats.American journal of physiology. Regulatory, integrative and comparative physiology · 2008Article
- The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system.PloS one · 2008Article
- Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.British journal of pharmacology · 2008Review
- The peripheral cannabinoid receptor knockout mice: an update.British journal of pharmacology · 2008Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Endocannabinoids and CB1 receptors have been implicated in endotoxin (LPS)-induced hypotension: LPS stimulates the synthesis of anandamide in macrophages, and the CB1 antagonist SR-141716 inhibits the hypotension induced by treatment of rats with LPS or LPS-treated macrophages. Recent evidence indicates the existence of cannabinoid receptors distinct from CB1 or CB2 that are inhibited by SR-141716 but not by other CB1 antagonists such as AM251. In pentobarbital-anesthetized rats, intravenous injection of 10 mg/kg LPS elicited hypotension associated with profound decreases in cardiac contractility, moderate tachycardia, and an increase in lower body vascular resistance. Pretreatment with 3 mg/kg SR-141716 prevented the hypotension and decrease in cardiac contractility, slightly attenuated the increase in peripheral resistance, and had no effect on the tachycardia caused by LPS, whereas pretreatment with 3 mg/kg AM251 did not affect any of these responses. SR-141716 also elicited an acute reversal of the hypotension and decreased contractility when administered after the response to LPS had fully developed. The LPS-induced hypotension and its inhibition by SR-141716 were similar in pentobarbital-anesthetized wild-type, CB1(-/-), and CB1(-/-)/CB2(-/-) mice. We conclude that SR-141716 inhibits the acute hemodynamic effects of LPS by interacting with a cardiac receptor distinct from CB1 or CB2 that mediates negative inotropy and may be activated by anandamide or a related endocannabinoid released during endotoxemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.